IN THE SPECIFICATION

Please amend the paragraph beginning on page 4, line 24, as follows:

A suitable acceptor must have an absorption spectrum overlapping the emission spectrum of the donor. For example, QSY 21TM is a suitable donor for use with Alexa Fluor 21TMALEXA FLUOR 21TM. It is desirable for an acceptor to have a wide absorption spectrum so that it can be used with a variety of donors.

Please amend the paragraph beginning on page 5, line 19, as follows:

Alexa Fluor 594TM ALEXA FLUOR 594TM is a dye with a suitable emission spectrum for use *in vivo*. This dye absorbs at 594 nm and fluoresces at 620 nm.

Please amend the paragraph beginning on page 8, line 27, as follows:

It is preferable for the lectin to be bound to the energy donor and the analyte analogue to be bound to the energy acceptor (e.g. Dextran-HMCV and Concanavalin A-Alexa Fluor 594TMALEXA FLUOR 594TM). Dextran can be more heavily labelled than Concanavalin A. If dextran is labelled with a fluorophore there will be excess fluorescence which dilutes the signal in a lifetime based assay.

Please amend the paragraph beginning on page 11, line 3, as follows:

Suitably, the energy donor is Alexa Fluor 594TM. ALEXA FLUOR 594TM.

Please amend the paragraph beginning on page 17, line 10, as follows:

The invention will be further described with reference to preferred embodiments illustrated by the Examples, and as illustrated in Figure 1, which shows a glucose dose-response curve, and Figure 2, which shows normalised absorption and emission spectra of Alexa Fluor 594ALEXA FLUOR 594TM and HMCV-1-dextran in aqueous PBS buffer 50 mM, pH=7.4 (Exitation of AF594 at 570 nm in a 0.7 μM solution).

NORRILD ET AL. Appl. No. 10/582,794 January 25, 2010

Please amend the heading beginning on page 27, line 22, as follows:

Attachment of Alexa Fluor 594TM ALEXA FLUOR 594TM to Concanavalin A (ConA)

Please amend the paragraph beginning on page 28, line 3, as follows:

To 13.0 mL of this solution was added Alexa Fluor 594TM ALEXA FLUOR 594TM (10.0 mg in 800 mL dry DMSO) in 20 μ L portions over 10 min. The resulting blue solution was stirred for 1 h and then succinic anhydride (18.2 mg in 867 μ L dry DMSO) was added in 20 μ L portions over 10 min. The solution was stirred for another 1.5 h after which it was transferred to a 15 mL dialysis slide and dialysed against the same buffer as described for the HMCV-1-Dextran synthesis. To the buffer was added 2 mM NaN₃ to prevent growth. (15.4 mL, concentration of protein dimer 59 μ M, DOL = 4.0)

Please amend the paragraph beginning on page 28, line 21, as follows:

Con A is labelled with Alexa Fluor 594™ ALEXA FLUOR 594™ (AF594) (donor) and dextran is labelled with a non–fluorescent dye, HMCV-1 (acceptor), absorbing within the emission band of AF594.